Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602020 | 1.00 | ATR (0.45) | ATRLMNAKMT2AALDH1A1RAB9A | |
| SCHEMBL29907839 | 0.86 | ATR (0.42) | ATRLMNAKMT2ABRD9BRD4 | |
| SCHEMBL23015391 | 0.86 | ATR (0.42) | ATRLMNAKMT2ABRD9BRD4 | |
| SCHEMBL31021950 | 0.86 | LMNA (0.43) | ATRLMNAKMT2AALDH1A1BRD9 | |
| SCHEMBL29692379 | 0.84 | ATR (0.49) | ATRLMNAKMT2AALDH1A1RAB9A | |
| SCHEMBL23015240 | 0.84 | ATR (0.49) | ATRLMNAKMT2AALDH1A1RAB9A | |
| SCHEMBL22411885 | 0.83 | ATR (0.42) | ATRLMNAKMT2AALDH1A1RAB9A | |
| SCHEMBL23608479 | 0.83 | KMT2A (0.42) | ATRLMNAKMT2ABRD9BRD4 | |
| SCHEMBL29883109 | 0.83 | KMT2A (0.42) | ATRLMNAKMT2ABRD9BRD4 | |
| SCHEMBL18383188 | 0.80 | ALDH1A1 (0.43) | LMNAKMT2AALDH1A1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028347-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4434990-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024158775-A1 | PYRIDAZINES AS SARM1 INHIBITORS | DISARM THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-3814357-B1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240132509-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-20210238186-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS HD, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238186-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS HD, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3814357-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112654625-A | Heterocyclic and heteroaryl compounds for the treatment of huntington's disease | PTC医疗公司 | 2021-04-13 | — | — | CN | disclosed |
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| CN-101098869-A | 5-heteroaryl thiazoles and their use as p13k inhibitors | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| EP-1841763-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006051270-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028347-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ATR 3703/4885LMNA 2198/4885KMT2A 2554/4885 |
| US-11858941-B2 | Heterocyclic and heteroaryl compounds for treating Huntington's disease | HTT, HYPK, FH | ATR 3855/4885LMNA 1626/4885KMT2A 1133/4885 |
| US-20210238186-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | ATR 3855/4885LMNA 1626/4885KMT2A 1133/4885 |
| US-20240132509-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HCN3, TRPV1 | ATR 4724/4885LMNA 3313/4885KMT2A 1843/4885 |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | ATR 635/4885LMNA 4256/4885KMT2A 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.